This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CTP-modified human growth hormone, hGH-CTP, long-acting hGH, MOD-401, MOD-4023, PF-06836922
Description: MOD-4023 is a long-acting human growth hormone that uses Carboxyl Terminal Peptide (CTP) technology. CTP is a short, naturally-occurring amino acid sequence that has the effect of slowing the removal/breakdown of the therapeutic protein to which it is attached, thereby extending the time that the protein is active in the body. The company feels that based on a primate study, a single injection of their long-acting growth hormone has the potential to be given weekly or bimonthly.
Deal Structure: In 2002, Modigene licensed CTP technology from Washington University (WashU) in Saint Louis exclusively for 11 therapeutic proteins, including Human Growth Hormone.
In February 2007, Modigene and WashU announced the signing of a definitive exclusive license expansion agreemnt that includes utilization of the CTP technology with all human therapeutic proteins, peptides and their modified forms except for three female fertility hormones that were previously out-licensed.
In June 2009, Modigene changed its name to PROLOR Biotech.
PROLOR and OPKO
In April 2013, OPKO and PROLOR announced that the companies signed a definitive merger agreement under which OPKO will acquire PROLOR in an all-stock transaction. Under the terms of the agreement holders of PROLOR common stock will receive 0.9951 shares of OPKO common stock for each share of PROLOR common stock. In August 2013, OPKO Health and PROLOR Biotech jointly announced the completion of the acquisition of PROLOR by...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Additional information available to subscribers only: